Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KY005
- Development stage
- Preclinical
- Lead developer
- KYDES Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Topical, Vaginal
01
Overview
KY005 (also known as KY1105) is an investigational therapeutic candidate being developed by KYDES Pharmaceuticals for the treatment of persistent human papillomavirus (HPV) infection and cervical dysplasia. It is described as a variation of the company's lead candidate, KY004. KYDES Pharmaceuticals focuses on developing non-invasive, topical treatments for HPV-related lesions to prevent progression to cervical cancer. While the exact mechanism of action for KY005 is not publicly detailed, it belongs to a pipeline of products designed to clear HPV infections and treat associated dysplastic changes. The drug is currently in the early stages of development.
- Other names
- KY1105KY-1105KY 1105
Beyond the preview
Go deeper on KY005.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KY005.